FDA Approves Premixed Version of Nexterone

Prism Pharmaceuticals Inc. Nov. 18 announced that the Food and Drug Administration has approved a premixed version of Nexterone (amiodarone HCL) injection.

Nexterone premixed injection is indicated for initiation of treatment and prophylaxis of frequently recurring ventricular fibrillation and hemodynamically unstable ventricular tachycardia in patients resistant to other therapy, the King of Prussia, Pa.-based company said. It is approved in two ready-to-use dosage forms with strengths of 1.5 mg/mL for rapid loading infusion and 1.8 mg/mL for subsequent infusion.

Manufacturer-prepared, premixed ready-to-use products represent a preferred approach, when available, to advance initiatives and professional standards for improving IV drug safety, ...